India, July 30 -- Alnylam Pharmaceuticals, Inc. (ALNY) plunged after lowering its full-year TTR revenue guidance, overshadowing strong second-quarter revenue growth and a return to profitability.
The stock is currently trading at $204.00, down $82.62 or 28.83%, on the Nasdaq. It opened at $225.03 after closing the previous session at $286.62. The stock has traded between $202.20 and $495.55 over the past 52 weeks.
Second-quarter total revenue surged 67% to $1.29 billion, while net product revenue climbed 74% to $1.17 billion, driven by an 89% increase in TTR franchise revenue to $1.03 billion.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The company reported net income of $164.5 million, or $1.21 ...